INDIANAPOLIS, Oct. 13, 2021 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has approved Eli Lilly and Company's (NYSE: LLY) Verzenio® (abemaciclib), in combination with endocrine therapy ...

INDIANAPOLIS, Sept. 27, 2021 /PRNewswire/ -- New data from Eli Lilly and Company's (NYSE: LLY) monarchE study for an investigational use of Verzenio® (abemaciclib), in combination with endocrine ...

Verzenio showed promising efficacy in high-grade meningiomas with CDK pathway or NF2 alterations, achieving progression-free survival at six months in 14 of 24 patients. Patients with NF2 alterations ...

As Eli Lilly looks to broaden use of its breast cancer drug Verzenio, the Big Pharma has teamed up with a big consortium of breast cancer organizations to help push awareness and understanding of the ...

Verzenio plus endocrine therapy reduced death risk by 15.8% in high-risk early breast cancer patients compared to endocrine therapy alone. The monarchE trial showed improved OS and IDFS rates with ...

Treatment with Verzenio plus endocrine therapy demonstrated a statistically significant and clinically meaningful improvement in overall survival compared to endocrine therapy alone In the seven-year ...

Pharmaceutical advancements continue to reshape the landscape of cancer treatment, offering new hope for patients and altering market dynamics. Recent developments in innovative therapies demonstrate ...

The MarketWatch News Department was not involved in the creation of this content. Incyclix Bio Announces Clinical Trial Collaboration and Supply Agreement with Lilly to Evaluate INX-315 in Combination ...

Please provide your email address to receive an email when new articles are posted on . The FDA expanded the approval of abemaciclib, combined with endocrine therapy, as adjuvant treatment for adults ...

Despite reaching new heights in breast cancer, Eli Lilly’s Verzenio has been sent packing in prostate cancer. Verzenio failed to significantly prolong the time before tumor progression or death when ...

Verzenio is the first contemporary therapy in over two decades to demonstrate a significant overall survival benefit in adjuvant HR+, HER2−, high-risk early breast cancer Seven-year results from the ...